Clinical Trial Update: Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and immunogenicity of the chikungunya virus-like particle vaccine PXVX0317 in adults aged 65 and older has completed, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Fever

Drugs mentioned

• PXVX0317 (CHIKV VLP Vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus | Phase 3 | Status: COMPLETED | Results posted: 2024-12-13